Malignant syndromes: current advances

References

• Schonfeldt-Lecuona C, Kuhlwilm L, Cronemeyer M, et al. Treatment of the Neuroleptic Malignant Syndrome in International Therapy Guidelines: a Comparative Analysis. Pharmacopsychiatry. 2020 Mar;53(2):51–59. .
   PubMed Web of Science ®Google Scholar
• Ryu HS, Yang SY. A case of refractory hypernatremia in the setting of parkinsonism-hyperpyrexia syndrome. Acta Neurol Belg. 2020 Mar;120(4):3.
   Web of Science ®Google Scholar
• Musselman ME, Saely S. Diagnosis and treatment of drug-induced hyperthermia. Am J Health Syst Pharm. 2013 Jan 1;70(1):34–42.
   PubMed Web of Science ®Google Scholar
• Rusyniak DE, Sprague JE. Toxin-induced hyperthermic syndromes. Med Clin North Am. 2005 Nov;89(6):1277–1296.
   PubMed Web of Science ®Google Scholar
• Pothen N, Kansal S, Rais T, et al. A Look at Genetic Linkage between Clozapine-induced Agranulocytosis, Malignant Hyperthermia, Neuroleptic Malignant Syndrome, and Statin-induced Myopathy. Innov Clin Neurosci. 2019 Nov 1;16(11–12):28–31.
   PubMedGoogle Scholar
• Kraeva N, Sapa A, Dowling JJ, et al. Malignant hyperthermia susceptibility in patients with exertional rhabdomyolysis: a retrospective cohort study and updated systematic review. Can J Anaesth. 2017 Jul;64(7):736–743. .
   PubMed Web of Science ®Google Scholar
• Yang L, Tautz T, Zhang S, et al. The current status of malignant hyperthermia. J Biomed Res. 2019 May 30;34(2):75–85.
   PubMed Web of Science ®Google Scholar
• Deuschl G, Oepen G, Hermle L, et al. Neuroleptic malignant syndrome: observations on altered consciousness. Pharmacopsychiatry. 1987 Jul;20(4):168–170. .
   PubMed Web of Science ®Google Scholar
• Otani K, Horiuchi M, Kondo T, et al. Is the predisposition to neuroleptic malignant syndrome genetically transmitted? Br J Psychiatry. 1991 Jun;158(6):850–853. .
   PubMed Web of Science ®Google Scholar
• Sato T, Nishio H, Iwata M, et al. Postmortem molecular screening for mutations in ryanodine receptor type 1 (RYR1) gene in psychiatric patients suspected of having died of neuroleptic malignant syndrome. Forensic Sci Int. 2010 Jan 30;194(1–3):77–79.
   PubMed Web of Science ®Google Scholar
• Suzuki A, Kondo T, Otani K, et al. Association of the TaqI A polymorphism of the dopamine D(2) receptor gene with predisposition to neuroleptic malignant syndrome. Am J Psychiatry. 2001 Oct;158(10):1714–1716. .
   PubMed Web of Science ®Google Scholar
• Santos JM, Andrade PV, Galleni L, et al. Idiopathic hyperCKemia and malignant hyperthermia susceptibility. Can J Anaesth. 2017 Dec;64(12):1202–1210. .
   PubMed Web of Science ®Google Scholar
• Langan J, Martin D, Shajahan P, et al. Antipsychotic dose escalation as a trigger for neuroleptic malignant syndrome (NMS): literature review and case series report. BMC Psychiatry. 2012 Nov 29;12(1):214.
   PubMed Web of Science ®Google Scholar
• Tse L, Barr AM, Scarapicchia V, et al. Neuroleptic Malignant Syndrome: a Review from a Clinically Oriented Perspective. Curr Neuropharmacol. 2015;13(3):395–406. .
   PubMed Web of Science ®Google Scholar
• Larach MG, Gronert GA, Allen GC, et al. Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006. Anesth Analg. 2010 Feb 1;110(2):498–507. .
   PubMed Web of Science ®Google Scholar
• Sahin A, Cicek M, Gonenc Cekic O, et al. A retrospective analysis of cases with neuroleptic malignant syndrome and an evaluation of risk factors for mortality. Turk J Emerg Med. 2017 Dec;17(4):141–145. .
   PubMed Web of Science ®Google Scholar
• Takubo H, Harada T, Hashimoto T, et al. A collaborative study on the malignant syndrome in Parkinson’s disease and related disorders. Parkinsonism Relat Disord. 2003 Apr;9(Suppl 1):S31–41. .
   PubMed Web of Science ®Google Scholar
• Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry. 1985 Oct;142(10):1137–1145.
   PubMed Web of Science ®Google Scholar
• Schneider M, Regente J, Greiner T, et al. Neuroleptic malignant syndrome: evaluation of drug safety data from the AMSP program during 1993-2015. Eur Arch Psychiatry Clin Neurosci. 2020 Feb;270(1):23–33. .
   PubMed Web of Science ®Google Scholar
• Serrano-Duenas M. Neuroleptic malignant syndrome-like, or–dopaminergic malignant syndrome–due to levodopa therapy withdrawal. Clinical features in 11 patients. Parkinsonism Relat Disord. 2003 Jan;9(3):175–178.
   PubMed Web of Science ®Google Scholar
• Velamoor VR, Norman RM, Caroff SN, et al. Progression of symptoms in neuroleptic malignant syndrome. J Nerv Ment Dis. 1994 Mar;182(3):168–173. .
   PubMed Web of Science ®Google Scholar
• Nagel M, Freisberg S, Junghanns K, et al. [The Neuroleptic Malignant Syndrome]. Fortschr Neurol Psychiatr. 2015 Jul;83(7):373–380. .
   PubMed Web of Science ®Google Scholar
• Denborough MA, Forster JF, Lovell RR, et al. Anaesthetic deaths in a family. Br J Anaesth. 1962 Jun;34(6):395–396. .
   PubMed Web of Science ®Google Scholar
• Britt BA, Kalow W. Malignant hyperthermia: a statistical review. Can Anaesth Soc J. 1970 Jul;17(4):293–315.
   PubMedGoogle Scholar
• Ellinas H, Albrecht MA. Malignant Hyperthermia Update. Anesthesiol Clin. 2020 Mar;38(1):165–181.
   PubMedGoogle Scholar
• Ording H. Incidence of malignant hyperthermia in Denmark. Anesth Analg. 1985 Jul;64(7):700–704.
   PubMed Web of Science ®Google Scholar
• Kollmann-Camaiora A, Alsina E, Dominguez A, et al. Clinical protocol for the management of malignant hyperthermia. Rev Esp Anestesiol Reanim. 2017 Jan;64(1):32–40. .
   PubMed Web of Science ®Google Scholar
• Brady JE, Sun LS, Rosenberg H, et al. Prevalence of malignant hyperthermia due to anesthesia in New York State, 2001-2005. Anesth Analg. 2009 Oct;109(4):1162–1166. .
   PubMed Web of Science ®Google Scholar
• Butala B, Brandom B. Muscular body build and male sex are independently associated with malignant hyperthermia susceptibility. Can J Anaesth. 2017 Apr;64(4):396–401.
   PubMed Web of Science ®Google Scholar
• Strazis KP, Fox AW. Malignant hyperthermia: a review of published cases. Anesth Analg. 1993 Aug;77(2):297–304.
   PubMed Web of Science ®Google Scholar
• Almeida CG, Colleti Junior J. MALIGNANT HYPERTHERMIA IN A CHILD AFTER MAGNETIC RESONANCE IMAGING: a CASE REPORT. Rev Paul Pediatr. 2020;38:e2018267.
   PubMedGoogle Scholar
• Chiba N, Matsuzaki M, Mawatari T, et al. Beneficial effects of dantrolene in the treatment of rhabdomyolysis as a potential late complication associated with COVID-19: a case report. Eur J Med Res. 2021 Feb 8;26(1):18.
   PubMed Web of Science ®Google Scholar
• Amador FJ, Stathopulos PB, Enomoto M, et al. Ryanodine receptor calcium release channels: lessons from structure-function studies. Febs J. 2013 Nov;280(21):5456–5470. .
   PubMed Web of Science ®Google Scholar
• Mackrill JJ. Ryanodine receptor calcium release channels: an evolutionary perspective. Adv Exp Med Biol. 2012;740:159–182.
   PubMed Web of Science ®Google Scholar
• Van Petegem F. Ryanodine receptors: structure and function. J Biol Chem. 2012 Sep 14;287(38):31624–31632.
   PubMed Web of Science ®Google Scholar
• Vemireddy LP, Aqeel A, Ying GW, et al. A Rare Case of RYR2 Mutation Causing Sudden Cardiac Arrest Due to Catecholaminergic Polymorphic Ventricular Tachycardia. Cureus. 2021 Feb 18;13(2):e13417.
   PubMed Web of Science ®Google Scholar
• Gong S, Su BB, Tovar H, et al. Polymorphisms Within RYR3 Gene Are Associated With Risk and Age at Onset of Hypertension, Diabetes, and Alzheimer’s Disease. Am J Hypertens. 2018 Jun 11;31(7):818–826.
   PubMed Web of Science ®Google Scholar
• Sedwick C. It’s time to look more closely at RYR3. J Gen Physiol. 2019 Jul 1;151(7):874.
   PubMed Web of Science ®Google Scholar
• Litman RS, Flood CD, Kaplan RF, et al. Postoperative malignant hyperthermia: an analysis of cases from the North American Malignant Hyperthermia Registry. Anesthesiology. 2008 Nov;109(5):825–829. .
   PubMed Web of Science ®Google Scholar
• Storey M, Hardy R, Kelly FE. Drawing up dantrolene for the treatment of malignant hyperthermia: use of a drawing up spike to make the process easier and quicker. Anaesthesia. 2020 Jun;75(6):835.
   PubMed Web of Science ®Google Scholar
• Schneiderbanger D, Johannsen S, Roewer N, et al. Management of malignant hyperthermia: diagnosis and treatment. Ther Clin Risk Manag. 2014;10:355–362.
   PubMed Web of Science ®Google Scholar
• Rosero EB, Adesanya AO, Timaran CH, et al. Trends and outcomes of malignant hyperthermia in the United States, 2000 to 2005. Anesthesiology. 2009 Jan;110(1):89–94. .
   PubMed Web of Science ®Google Scholar
• Delay J, Pichot P, Lemperiere T, et al. A non-phenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychoses. Ann Med Psychol. 1960 Jan;118(1):145–152.
   PubMedGoogle Scholar
• Belvederi Murri M, Guaglianone A, Bugliani M, et al. Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis. Drugs R D. 2015 Mar;15(1):45–62. .
   PubMed Web of Science ®Google Scholar
• Nayak RB, Bhogale GS, Patil NM, et al. Paliperidone-induced neuroleptic malignant syndrome. J Neuropsychiatry Clin Neurosci. 2011;23(1):E14–5. .
   PubMed Web of Science ®Google Scholar
• Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am. 1993 Jan;77(1):185–202.
   PubMed Web of Science ®Google Scholar
• Spivak B, Maline DI, Kozyrev VN, et al. Frequency of neuroleptic malignant syndrome in a large psychiatric hospital in Moscow. Eur Psychiatry. 2000 Aug;15(5):330–333. .
   PubMed Web of Science ®Google Scholar
• Kane JM, Correll CU, Delva N, et al. Low Incidence of Neuroleptic Malignant Syndrome Associated With Paliperidone Palmitate Long-Acting Injectable: a Database Report and Case Study. J Clin Psychopharmacol. 2019;39(2):180–182. .
   PubMed Web of Science ®Google Scholar
• Nakamura M, Yasunaga H, Miyata H, et al. Mortality of neuroleptic malignant syndrome induced by typical and atypical antipsychotic drugs: a propensity-matched analysis from the Japanese Diagnosis Procedure Combination database. J Clin Psychiatry. 2012 Apr;73(4):427–430. .
   PubMed Web of Science ®Google Scholar
• Gurrera RJ. A systematic review of sex and age factors in neuroleptic malignant syndrome diagnosis frequency. Acta Psychiatr Scand. 2017 May;135(5):398–408.
   PubMed Web of Science ®Google Scholar
• Margetic B, Aukst-Margetic B. Neuroleptic malignant syndrome and its controversies. Pharmacoepidemiol Drug Saf. 2010 May;19(5):429–435.
   PubMed Web of Science ®Google Scholar
• Pileggi DJ, Cook AM. Neuroleptic Malignant Syndrome. Ann Pharmacother. 2016 Nov;50(11):973–981.
   PubMed Web of Science ®Google Scholar
• Berardi D, Amore M, Keck PE Jr., et al. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: a case-control study. Biol Psychiatry. 1998 Oct 15;44(8):748–754.
   PubMed Web of Science ®Google Scholar
• Gurrera RJ. Is neuroleptic malignant syndrome a neurogenic form of malignant hyperthermia? Clin Neuropharmacol. 2002 Jul-Aug;25(4):183–193.
   PubMed Web of Science ®Google Scholar
• Araki M, Takagi A, Higuchi I, et al. Neuroleptic malignant syndrome: caffeine contracture of single muscle fibers and muscle pathology. Neurology. 1988 Feb;38(2):297–301. .
   PubMed Web of Science ®Google Scholar
• Van Rensburg R, Decloedt EH. An Approach to the Pharmacotherapy of Neuroleptic Malignant Syndrome. Psychopharmacol Bull. 2019 Feb 15;49(1):84–91.
   PubMedGoogle Scholar
• Gurrera RJ, Mortillaro G, Velamoor V, et al. A Validation Study of the International Consensus Diagnostic Criteria for Neuroleptic Malignant Syndrome. J Clin Psychopharmacol. 2017 Feb;37(1):67–71. .
   PubMed Web of Science ®Google Scholar
• Strawn JR, Keck PE Jr., Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry. 2007 Jun;164(6):870–876.
   PubMed Web of Science ®Google Scholar
• Vickery PB, Meadowcraft L, Vickery SB. Early detection of an atypical presentation of neuroleptic malignant syndrome: a case report. Ment Health Clin. 2017 May;7(3):137–142.
   PubMedGoogle Scholar
• Modi S, Dharaiya D, Schultz L, et al. Neuroleptic Malignant Syndrome: complications, Outcomes, and Mortality. Neurocrit Care. 2016 Feb;24(1):97–103. .
   PubMed Web of Science ®Google Scholar
• Gonzalez-Blanco L, Garcia-Prada H, Santamarina S, et al. Recurrence of neuroleptic malignant syndrome. Actas Esp Psiquiatr. 2013 Sep-Oct;41(5):314–318.
   PubMed Web of Science ®Google Scholar
• Mendhekar DN, Jiloha RC, Mehndiratta MM, et al. Challenge with atypical antipsychotic drugs in risperidone induced neuroleptic malignant syndrome: a case report. Indian J Psychiatry. 2002 Oct;44(4):387–390.
   PubMedGoogle Scholar
• Fujitake J, Kuno S, Nishitani H. [Neuroleptic malignant syndrome-like state in eight patients with parkinsonism]. Rinsho Shinkeigaku. 1984 Apr;24(4):371–378.
   PubMedGoogle Scholar
• Newman EJ, Grosset DG, Kennedy PG. The parkinsonism-hyperpyrexia syndrome. Neurocrit Care. 2009;10(1):136–140.
   PubMed Web of Science ®Google Scholar
• Granner MA, Wooten GF. Neuroleptic malignant syndrome or parkinsonism hyperpyrexia syndrome. Semin Neurol. 1991 Sep;11(3):228–235.
   PubMed Web of Science ®Google Scholar
• Harada T, Mitsuoka K, Kumagai R, et al. Clinical features of malignant syndrome in Parkinson’s disease and related neurological disorders. Parkinsonism Relat Disord. 2003 Apr;9(Suppl 1):S15–23. .
   PubMed Web of Science ®Google Scholar
• Onofrj M, Thomas A. Acute akinesia in Parkinson disease. Neurology. 2005 Apr 12;64(7):1162–1169.
   PubMed Web of Science ®Google Scholar
• Arora A, Fletcher P. Parkinsonism hyperpyrexia syndrome caused by abrupt withdrawal of ropinirole. Br J Hosp Med. 2013 Dec;74(12):698–699.
   Web of Science ®Google Scholar
• Hamada Y, Miyamoto K, Inatsugi Y, et al. A case of Parkinson’s disease with neuroleptic malignant syndrome induced by paroxetine. Rinsho Shinkeigaku. 2006 Aug;46(8):575–578.
   PubMedGoogle Scholar
• Grover S, Sathpathy A, Reddy SC, et al. Parkinsonism-hyperpyrexia syndrome: a case report and review of literature. Indian J Psychiatry. 2018 Oct-Dec;60(4):499–503. .
   PubMed Web of Science ®Google Scholar
• Kaasinen V, Joutsa J, Noponen T, et al. Akinetic crisis in Parkinson’s disease is associated with a severe loss of striatal dopamine transporter function: a report of two cases. Case Rep Neurol. 2014 Sep;6(3):275–280. .
   PubMedGoogle Scholar
• Govindappa ST, Abbas MM, Hosurkar G, et al. Parkinsonism Hyperpyrexia Syndrome following Deep Brain Stimulation. Parkinsonism Relat Disord. 2015 Oct;21(10):1284–1285. .
   PubMed Web of Science ®Google Scholar
• Ikebe S, Harada T, Hashimoto T, et al. Prevention and treatment of malignant syndrome in Parkinson’s disease: a consensus statement of the malignant syndrome research group. Parkinsonism Relat Disord. 2003 Apr;9(Suppl 1):S47–9. .
   PubMed Web of Science ®Google Scholar
• Mizuno Y, Takubo H, Mizuta E, et al. Malignant syndrome in Parkinson’s disease: concept and review of the literature. Parkinsonism Relat Disord. 2003 Apr;9(Suppl 1):S3–9. .
   PubMed Web of Science ®Google Scholar
• Lejoyeux M, Fineyre F, Adès J. The serotonin syndrome. Am J Psychiatry. 1992 Oct;149(10):1410–1411.
   PubMed Web of Science ®Google Scholar
• Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005 Mar 17;352(11):1112–1120.
   PubMed Web of Science ®Google Scholar
• Adnet P, Lestavel P, Krivosic-Horber R. Neuroleptic malignant syndrome. Br J Anaesth. 2000 Jul;85(1):129–135.
   PubMed Web of Science ®Google Scholar
• Richter E, Baldovini A, Blasco V, et al. About baclofen withdrawal syndrome. Presse Med. 2016 May;45(5):547–548. .
   PubMed Web of Science ®Google Scholar
• Paul V, Righter K, Kim E, et al. Severe hyperthermia due to oral baclofen withdrawal. BMJ Case Rep. 2020;13(9):e234710.
   PubMedGoogle Scholar
• Gottula AL, Gorder KL, Peck AR, et al. Dexmedetomidine for Acute Management of Intrathecal Baclofen Withdrawal. J Emerg Med. 2019 Nov;20. DOI:https://doi.org/10.1016/j.jemermed.2019.09.043
   Google Scholar
• Maravi P, Mishra DK, Singh A, et al. Atropine eye-drop-induced acute delirium: a case report. Gen Psychiatr. 2020;33(3):e100125. .
   PubMed Web of Science ®Google Scholar
• Knuf KM, Spaulding FM, Stevens GJ. Scopolamine Toxicity in an Elderly Patient. Mil Med. 2019 Dec 1;184(11–12):937–938.
   PubMed Web of Science ®Google Scholar
• Moos DD. Central anticholinergic syndrome: a case report. J Perianesth Nurs. 2007 Oct;22(5):309–321.
   PubMedGoogle Scholar
• Bienvenu OJ, Neufeld KJ, Needham DM. Treatment of four psychiatric emergencies in the intensive care unit. Crit Care Med. 2012 Sep;40(9):2662–2670.
   PubMed Web of Science ®Google Scholar
• Koleva K, Pavlov O, Nikolov R, et al. Deep brain stimulation as a possible treatment of hyperthermia in patients with serotonin syndrome. Med Hypotheses. 2020 Apr;1(139):109704. .
   Web of Science ®Google Scholar
• Amano T, Fukami T, Ogiso T, et al. Identification of enzymes responsible for dantrolene metabolism in the human liver: a clue to uncover the cause of liver injury. Biochem Pharmacol. 2018 May;151:69–78.
   PubMed Web of Science ®Google Scholar
• Paden MS, Franjic L, Halcomb SE. Hyperthermia caused by drug interactions and adverse reactions. Emerg Med Clin North Am. 2013 Nov;31(4):1035–1044.
   PubMed Web of Science ®Google Scholar
• Bhanushali MJ, Tuite PJ. The evaluation and management of patients with neuroleptic malignant syndrome. Neurol Clin. 2004 May;22(2):389–411.
   PubMed Web of Science ®Google Scholar
• Rosenberg MR, Green M. Neuroleptic malignant syndrome. Review of response to therapy. Arch Int Med. 1989 Sep;149(9):1927–1931.
   PubMedGoogle Scholar
• Hirjak D, Sartorius A, Kubera KM, et al. Antipsychotic-inducedmotor symptoms in schizophrenic psychoses-Part 2. Catatonic symptoms and neuroleptic malignant syndrome. Nervenarzt 2019 Jan;90(1):12–24. .
   PubMed Web of Science ®Google Scholar
• Sakkas P, Davis JM, Janicak PG, et al. Drug treatment of the neuroleptic malignant syndrome. Psychopharmacol Bull. 1991;27(3):381–384.
   PubMedGoogle Scholar
• Trollor JN, Sachdev PS. Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. Aust N Z J Psychiatry. 1999 Oct;33(5):650–659.
   PubMed Web of Science ®Google Scholar
• Morcos N, Rosinski A, Maixner DF. Electroconvulsive Therapy for Neuroleptic Malignant Syndrome: a Case Series. J Ect. 2019 Dec;35(4):225–230.
   PubMed Web of Science ®Google Scholar
• Luchini F, Medda P, Mariani MG, et al. Electroconvulsive therapy in catatonic patients: efficacy and predictors of response. World J Psychiatry. 2015 Jun 22;5(2):182–192.
   PubMed Web of Science ®Google Scholar
• Auffret M, Drapier S, Verin M. New tricks for an old dog: a repurposing approach of apomorphine. Eur J Pharmacol. 2019 Jan;15(843):66–79.
   Web of Science ®Google Scholar